Moderna secures up to $50 million to develop an Ebola vaccine.

In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine ...

By Jennifer Rigby, Mariam Sunny and Julie Steenhuysen June 1 (Reuters) - Global health organisation CEPI will give roughly ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

CEPI is committing up to $50 million to support Moderna's vaccine candidate for the strain with no approved shot ...

Global health foundation Coalition for Epidemic Preparedness Innovations (CEPI) will invest $50 million to support ...

Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical ...

A top adviser has resigned from the Food and Drug Administration's (FDA) vaccine advisory committee amid concerns about her ...

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Study results released on Monday revealed that a personalized mRNA vaccine manufactured by Moderna and Merck has shown ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...